Hi Geo,
Cxbladder(detect) is quantifiable as it's in the market place already, but a takeover candidate would also need to value the prospective product pipeline which PEB have invested years of very smart R&D and funding into.
Cxbladder(triage), Cxbladder(predict), Cxcolorectal, melanoma, gastric, endometrial etc and whatever else may be in earlier in development. Also, I think the access to research from the University of Otago has a value also.
Not to mention the patents, all that proprietary IP, and the regulatory approved operational laboratories in the US and NZ, and partnered lab agreement access in Australia and Spain.
By my assessment PEB Cxbladder(detect) alone is conservatively worth as a minimum $1.70.
I would scoff at a takeover bid short of $4.00, probably would not support one at all.
It’s gone a bit quiet since all that buzz back in December, mostly from the Brokers, Craig’s in particular, in the articles below,
http://www.nzherald.co.nz/business/n...ectid=11178639
http://www.odt.co.nz/news/business/2...-edge-business
regards, Mac